Rimonabant for the treatment of obesity

Ashish Samat, Brian Tomlinson, Shahrad Taheri, G. Neil Thomas

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocannabinoid system (ECS) was discovered in the early 1990s in relation to work on the action of components of marijuana. Central activation of the ECS promotes food ingestion. The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2. CB1 receptors are located predominantly in the brain and peripherally in adipose tissue, liver, skeletal muscle and the gastrointestinal tract. In July 2006, European regulatory authorities approved the use of rimonabant, SR141716, a selective CB1 receptor antagonist, in obese patients (BMI ≥30kg/m2, or >27kg/m2 with complications). However, in June 2007, despite extensive clinical trial data, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the safety of rimonabant had not been adequately demonstrated by the manufacturer Sanofi-Aventis; the full application was subsequently withdrawn. This review article provides evidence and outlines some patents for the use of rimonabant and potential safety concerns which still prevent its use in the single largest market for drugs of its kind.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalRecent Patents on Cardiovascular Drug Discovery
Volume3
Issue number3
DOIs
Publication statusPublished - 2008
Externally publishedYes

    Fingerprint

Keywords

  • ARPEGGIO
  • AUDITOR
  • CRESCENDO
  • Endocannabinoid system
  • Obesity
  • RAPSODI
  • Rimonabant
  • RIO ADAGIO-Lipids
  • SERENADE
  • STRADIVARIUS
  • Vascular disease risk factors
  • VICTORIA
  • Visceral fat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this